Project Summary This is an application for a Research Supplement to Promote Diversity in Health-Related Research (PA-18-906). The parent R01 project associated with this application is entitled “(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer” supported by NCI (5R01CA230854-02). Brandon Dale is the diversity candidate. He is a US citizen of African-American descent and is currently an MD/PhD graduate student at Icahn School of Medicine at Mount Sinai, New York. The main goal of this study is to characterize a set of EZH2 degraders in triple-negative breast cancer cellular models.